secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0000917520-25-000004
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences receives FDA warning letter for quality system violations at three facilities
--------------------------------------------------------------------------------

- FDA warning letter dated Dec 19, 2024, for quality system issues at Mansfield, MA; Plainsboro, NJ; Princeton, NJ facilities.
- Products cited: cranial perforators, cottonoid patties, strips, collagen-based products; shipping holds and voluntary recall of patties/strips previously initiated.
- Warning letter does not restrict manufacturing/shipment or require recall; premarket approval for related Class III devices blocked until violations resolved.
- Company reaffirms Q4 revenue guidance of $441M-$451M; expects no material impact from warning letter.
- Company is executing a compliance master plan and preparing a written response to the FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000004/0000917520-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000004/iart-20241219.htm
  HTML page:      https://secwatch.observer/filing/0000917520-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer